Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix When Administered According to the Prescribing Information to Indian Infants.

Trial Profile

Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix When Administered According to the Prescribing Information to Indian Infants.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions
  • Acronyms ROTA-071 PMS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Aug 2010 Status changed from completed to active, no longer recruiting as reported by Clinical Trials Registry - India.
    • 04 May 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top